In staging intermediate to high-risk PCa, PET/CT with 68Ga-PSMA-targeted agents had a higher sensitivity compared to MR (65% versus 41%, respectively) and similar specificity (94% versus 92%, respectively) in detecting lymph nodal metastases [23]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.